ZIM
OSIR

Zacks Investment Management’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Zacks Investment Management’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-13,339
Closed -$260K – 756
2015
Q2 		$260K Buy
+13,339
New +$236K 0.01% 552

Other funds holding OSIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Zacks Investment Management's OSIR Position: Q3 2015 in Review

Zacks Investment Management sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q3 2015, closing a stake of 13,339 shares — an estimated $260K sold.

Zacks Investment Management first reported a position in OSIR in Q2 2015 and held it in 1 quarter. The position peaked at $260K in Q2 2015. 92 funds tracked by Wall St. Rank hold OSIR as of Q3 2015.

  • Zacks Investment Management reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Zacks Investment Management sold 13,339 Osiris Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $260K.
  • Zacks Investment Management first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2015 and held it in 1 quarter.
  • Zacks Investment Management's Osiris Therapeutics, Inc. Common Stock position peaked at $260K in Q2 2015.
  • 92 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Zacks Investment Management's 13F filing for Q3 2015, filed 12 Nov 2015.